allapinin and Chronic-Disease

Echocardiographic study was performed in 24 patients with persistent atrial fibrillation (PAF) without clinical signs of circulatory failure. When treated with allapinin , all the patients with PAF showed a significant increase in heart rate (HR) and cardiac output (CO) and a decrease in total peripheral vascular resistance (TPVR). No substantial changes in the major hemodynamic parameters were found in patients with higher left ventricular dimensions; however, a significant rise in end systolic volume (ESV) was noted. There was significantly lower HR, diminished ESV, higher stroke volume and increased CO, elevated ejection fraction and TPVR with sinus rhythm. In PAF patients without apparent signs of circulatory failure, hemodynamic effects of allapinin may be accounted for by its direct vasodilatory action on the arterial bed and by its ability to affect cardiac autonomic innervation. A moderate cardiodepressive effect of the agent may be reflected by deteriorated latent signs of myocardial incompetence which are levelled off following sinus rhythm recovery.

Topics: Aconitine; Aconitum; Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Clinical Trials as Topic; Hemodynamics; Humans; Male; Middle Aged; Sinoatrial Node; Stimulation, Chemical; Tablets

Effect of a new antiarrhythmic drug allapinin was studied in 21 patients with chronic ventricular extrasystoles by an acute drug test with single oral dose of the drug controlled by 12-hour Holter monitoring. In 9 cases the dose was 50 mg. Maximal total reduction of ventricular ectopic complexes (VEC) per hour was 67 +/- 28% (mean value); in 5 cases (55%) it exceeded 90% of basal level. At peak of action, PQ interval increased by 15%, QRS--by 14%, QT was not significantly changed. In 14 cases the dose was 75 micrograms. Maximal VEC number reduction per hour was on the average 89 +/- 18% and in 12 cases (88%) exceeded 90%. PQ increased by 22%, QRS--by 23% and QT by 9% though JT was not changed (average peak values). It is thus concluded that single oral dose of allapinin has pronounced antiarrhythmic effect in patients with VEC and influences ECG intervals in the way characteristic for class IC antiarrhythmic drugs. The degree of the effect depends on the dose.

Topics: Aconitine; Aconitum; Administration, Oral; Adult; Cardiac Complexes, Premature; Chronic Disease; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Heart Ventricles; Humans; Male; Middle Aged

Clinical assessment of a new antiarrhythmic drug, allapinin, was carried out in 42 patients with chronic ventricular extrasystoles. Single intravenous doses were effective where they exceeded 0.32 mg/kg. Doses above 0.42 mg/kg were regularly associated with side effects, such as dizziness or, less commonly, diplopia. The 0.39 mg/kg dose produced an antiarrhythmic effect in 61% of patients, whose PQ interval was lengthened by 23%, and the QRS complex, by 18%, while QTc duration remained unchanged. Heart rate and arterial blood pressure were virtually unchanged, either. The peak of antiarrhythmic effect fell to the second postadministration hour, and the effect persisted within an average of 7.6 hours. Therefore, allapinin appears to be a potent quinidine-like agent.

Topics: Aconitine; Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Chronic Disease; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Heart Conduction System; Heart Ventricles; Humans; Injections, Intravenous; Male; Middle Aged

A double blind randomized cross-over study was conducted to analyze antiarrhythmic activity of the new Soviet drugs allapinin , ethacizine in comparison with mexitil. Altogether 33 patients with ventricular disorders of cardiac rhythm of high gradations after Lown B. were investigated including patients with paroxysmal ventricular tachycardia. The authors managed to establish and compare the group antiarrhythmic efficacy and safety of each drug, and to assess a degree of selective efficacy of each of them.

Topics: Aconitine; Aconitum; Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Female; Humans; Male; Mexiletine; Middle Aged; Phenothiazines; Random Allocation; Tachycardia, Ectopic Junctional; Tachycardia, Paroxysmal; Tachycardia, Supraventricular

During a prolonged (24-hour) intravenous administration in a dose of 126 mg, allapinine produced a stable pronounced antiarrhythmic effect in 90% of the patients with frequent premature ventricular contraction and adverse reactions in the central nervous system in 65% of the cases. However, the latter effect of allapinine is short-term and ceased independently without altering the infusion rate. More serious adverse effects (hypotensive reactions, proarhythmic effects) occurred in 4% of the cases.

Topics: Aconitine; Adult; Aged; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Chronic Disease; Coronary Disease; Female; Humans; Infusions, Intravenous; Male; Middle Aged

The cardiorespiratory system was studied comprehensively in 27 patients with permanent atrial fibrillation (PAF) without the clinically marked signs of circulatory failure. After allapinine treatment 15 patients with bronchial obstruction manifestations demonstrated, in the presence of lasting PAF, a significant increase of the forced expiration capacity per s and of the maximum volumetric expiration rates. The data obtained may attest to the fact that the drug has beta-stimulating properties, confirming the reported evidence.

Topics: Aconitine; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bronchodilator Agents; Cardiovascular Diseases; Chronic Disease; Humans; Male; Middle Aged; Respiration; Respiratory Function Tests